



Nevada PEBP

Q2 FY2025

Prepared by Client Analytics

Cynthia Eaton (cynthia.eaton@express-scripts.com)

02/28/2025

**The data contained herein is pulled from a specific point-in-time and is subject to change at any time without notice due to a variety of factors, including but not limited to changes related to Member behavior, population demographics, system updates, and product availability. The data does not represent a guarantee and should not be used for audit purposes.*

Hello PEBP Team,

This is the Q2 FY25 Summary File for the three State of Nevada PEBP plans (CDHP, EPO, and PPO). The summary contains Trend breakouts for each plan (Utilization, Unit Cost, and Cost Share). Along with the most notable changes of drugs within the top moving indications. Each plan breakout has a peer comparison of Trend. The file concludes with several Key Statistics of the three plans in aggregate.

CDHP Overall Trend Summaries:

CDHP Overall Trend		% Change
Current Period - Plan Cost Net PMPM	\$71.89	
Utilization	\$3.37	4.6%
Unit Cost	(\$0.75)	(1.0%)
Member Share	(\$3.19)	(4.4%)
Total Change in Plan Cost Net PMPM	(\$0.57)	(0.8%)
Previous Period - Plan Cost Net PMPM	\$72.47	

Top moving indications and most notable drug changes within the indications are as follows:

- **Inflammatory Conditions:** Previous ranked 1st, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↓ \$274k (-14.3%) to current \$1.6m.
 - Plan Cost Net PMPM ↓ \$1.21 (-9.2%) to current \$11.95.
 - Patient Count ↓ 8 to current count of 214.
 - Adjusted Rx's ↓ 13 to current count of 1,163.
- **Notable Drug Changes within Indication:**
 - **Skyrizi Pen:**
 - Previous ranked 3rd, currently ranked 1st, by Plan Cost Net.
 - Plan Cost Net ↑ \$68k (41.0%) to current \$233k.
 - Plan Cost Net PMPM ↑ \$.56 (49.4%) to current \$1.70.
 - Patient Count: Remains at 9.
 - Adjusted Rx's ↑ 11 to current count of 59.
 - **Humira(CF) Pen:**
 - Previous ranked 1st, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↓ \$317k (-65.3%) to current \$168k.
 - Plan Cost Net PMPM ↓ \$2.10 (-65.3%) to current \$1.22.
 - Patient Count ↓ 4 to current count of 26.
 - Adjusted Rx's ↓ 53 to current count of 92.

- **Rinvoq:**
 - Previous ranked 8th, currently ranked 3rd, by Plan Cost Net.
 - Plan Cost Net ↑ \$72k (81.9%) to current \$160k.
 - Plan Cost Net PMPM ↑ \$.56 (92.8%) to current \$1.16.
 - Patient Count ↑5 to current count of 11.
 - Adjusted Rxs ↑23 to current count of 50.

- **Stelara:**
 - Previous ranked 2nd, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↓ \$71k (-32.2%) to current \$150k.
 - Plan Cost Net PMPM ↓ \$.43 (-28.2%) to current \$1.09.
 - Patient Count ↓1 to current count of 6.
 - Adjusted Rxs ↓7 to current count of 38.

- **HIV:** Previous ranked 5th, currently ranked 5th by Plan Cost Net.
 - Plan Cost Net ↑ \$112k (16.5%) to current \$787k.
 - Plan Cost Net PMPM ↑ \$1.09 (23.5%) to current \$5.72.
 - Patient Count ↑15 to current count of 107.
 - Adjusted Rxs ↑65 to current count of 529.

- **Notable Drug Changes within Indication:**
 - **Biktarvy:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$68k (33.3%) to current \$273k.
 - Plan Cost Net PMPM ↑ \$.58 (41.3%) to current \$1.99.
 - Patient Count ↑5 to current count of 20.
 - Adjusted Rxs ↑20 to current count of 97.

 - **Descovy:**
 - Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$22k (12.3%) to current \$199k.
 - Plan Cost Net PMPM ↑ \$.23 (19.0%) to current \$1.45.
 - Patient Count ↑8 to current count of 34.
 - Adjusted Rxs ↑36 to current count of 160.

 - **Triumeq:**
 - Previous ranked 4th, currently ranked 7th by Plan Cost Net.
 - Plan Cost Net ↓ \$19k (-33.2%) to current \$38k.
 - Plan Cost Net PMPM ↓ \$.12 (-29.2%) to current \$.28.
 - Patient Count ↓2 to current count of 3.
 - Adjusted Rxs ↓9 to current count of 16.

- **Blood Cell Deficiency:** Previous ranked 55th, currently ranked 10th by Plan Cost Net.
 - Plan Cost Net ↑ \$199k (3007.9%) to current \$205k.
 - Plan Cost Net PMPM ↑ \$1.45 (3194.2%) to current \$1.49.
 - Patient Count ↑3 to current count of 6.
 - Adjusted Rxs ↑4 to current count of 15.

- **Notable Drug Changes within Indication:**
 - **Promacta:**
 - New, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current \$181k.
 - Plan Cost Net PMPM: New, current \$1.32.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 5.

 - **Doptelet:**
 - New, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net: New, current \$18k.
 - Plan Cost Net PMPM: New, current \$.13.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 3.

 - **Other drug changes in this indication were not notable.**

- **Gout:** Previous ranked 68th, currently ranked 12th by Plan Cost Net.
 - Plan Cost Net ↑ \$184k (9545.7%) to current \$186k.
 - Plan Cost Net PMPM ↑ \$1.34 (10123.9%) to current \$1.35.
 - Patient Count ↓22 to current count of 279.
 - Adjusted Rxs ↓53 to current count of 1,361.

- **Krystexxa:**
 - New, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current \$183k.
 - Plan Cost Net PMPM: New, current \$1.33.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 4.

- **Other drug changes in this indication were not notable.**

Peer Comparison:

- Peer: ESI CDH Program
- PEBP CDHP is outperforming the peer.
- Peer experienced Plan Cost Net PMPM of \$102.83 compared to CDHP PEBP of \$71.89.
- Peer experienced Trend of 15.8%, compared to CDHP PEBP Trend of -0.8%

EPO Overall Trend Summaries:

EPO Overall Trend		% Change
Current Period - Plan Cost Net PMPM	\$179.51	
Utilization	\$9.99	6.4%
Unit Cost	\$15.51	9.9%
Member Share	(\$2.89)	(1.8%)
Total Change in Plan Cost Net PMPM	\$22.61	14.4%

Previous Period - Plan Cost Net PMPM **\$156.90**

Top moving indications and most notable drug changes within the indications are as follows:

- **Inflammatory Conditions:** Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↓ \$154k (-14.6%) to current \$903k.
 - Plan Cost Net PMPM ↓ \$1.65 (-5.4%) to current \$28.75.
 - Patient Count ↓3 to current count of 117.
 - Adjusted Rxs ↓56 to current count of 667.
- **Notable Drug Changes within Indication:**
 - **Tavneos:**
 - Previous ranked 2nd, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$64k (51.0%) to current \$190k.
 - Plan Cost Net PMPM ↑ \$2.43 (67.1%) to current \$6.05.
 - Patient Count: Remains at 2.
 - Adjusted Rxs ↑4 to current count of 13.
 - **Adalimumab-Ryvok(CF) Autoinject (Biosimilar for Humira(CF)Pen)**
 - New, currently ranked 6th by Plan Cost Net.
 - Plan Cost Net: New, current \$59k.
 - Plan Cost Net PMPM: New, current \$1.88.
 - Patient Count: New, current count of 14.
 - Adjusted Rxs: New, current count of 57.

- **Humira(CF) Pen:**
 - Previous ranked 1st, currently ranked 10th by Plan Cost Net.
 - Plan Cost Net ↓ \$260k (-92.0%) to current \$23k.
 - Plan Cost Net PMPM ↓ \$7.40 (-91.1%) to current \$.72.
 - Patient Count ↓8 to current count of 12.
 - Adjusted Rxs ↓66 to current count of 42.

- **Cancer:** Previous ranked 4th, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net ↑ \$216k (50.1%) to current \$647k.
 - Plan Cost Net PMPM ↑ \$8.19 (66.1%) to current \$20.57.
 - Patient Count ↓9 to current count of 58.
 - Adjusted Rxs ↑2 to current count of 294.

- **Notable Drug Changes within Indication:**
 - **Koselugo:**
 - New, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net: New, current \$113k.
 - Plan Cost Net PMPM: New, current \$3.59.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 5.

 - **Venclexta:**
 - Previous ranked 4th, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net ↑ \$61k (149.4%) to current \$101k.
 - Plan Cost Net PMPM ↑ \$2.05 (176.0%) to current \$3.22.
 - Patient Count ↑1 to current count of 2.
 - Adjusted Rxs ↑3 to current count of 7.

 - **Erleada:**
 - Previous ranked 9th, currently ranked 5th by Plan Cost Net.
 - Plan Cost Net ↑ \$61k (798.5%) to current \$69k.
 - Plan Cost Net PMPM ↑ \$1.98 (894.4%) to current \$2.20.
 - Patient Count: Remains at 1.
 - Adjusted Rxs ↑5 to current count of 6.

- **Seizures:** Previous ranked 7th, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↑ \$155k (94.8%) to current \$318k.
 - Plan Cost Net PMPM ↑ \$5.43 (115.6%) to current \$10.13.
 - Patient Count ↓26 to current count of 189.
 - Adjusted Rxs ↓72 to current count of 1,122.

- **Notable Drug Changes within Indication:**

- **Fintepla:** Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$150k (159.2%) to current \$244k.
 - Plan Cost Net PMPM ↑ \$5.06 (186.8%) to current \$7.78.
 - Patient Count ↑1 to current count of 2.
 - Adjusted Rxs ↑8 to current count of 13.

- **Other drug changes in this indication were not notable.**

- **Endocrine Disorders:** Previous ranked 2nd, currently ranked 8th by Plan Cost Net.
 - Plan Cost Net ↓ \$551k (-74.3%) to current \$191k.
 - Plan Cost Net PMPM ↓ \$15.25 (-71.5%) to current \$6.07.
 - Patient Count ↑3 to current count of 28.
 - Adjusted Rxs ↑17 to current count of 124.

- **Notable Drug Changes within Indication:**
 - **Korlym:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↓ \$622k (-88.6%) to current \$80k.
 - Plan Cost Net PMPM ↓ \$17.65 (-87.4%) to current \$2.55.
 - Patient Count: Remains at 2.
 - Adjusted Rxs ↓10 to current count of 2.

 - **Supprelin LA:**
 - New, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net: New, current \$49k.
 - Plan Cost Net PMPM: New, current \$1.55.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 12.

 - **Other drug changes in this indication were not notable.**

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP EPO plan)
- The peer is outperforming PEBP EPO in Plan Cost Net PMPM but underperforming in Trend.
- Peer experienced Plan Cost Net PMPM of \$130.06 compared to PEBP EPO of \$179.51
- Peer experienced Trend of 20.9%, compared to PEBP EPO of 14.4%

PPO Overall Trend Summaries:

PPO Overall Trend		% Change
Current Period - Plan Cost Net PMPM	\$102.65	
Utilization	\$5.03	5.3%
Unit Cost	\$2.78	2.9%
Member Share	(\$0.49)	(50.0%)
Total Change in Plan Cost Net PMPM	\$7.32	7.7%
Previous Period - Plan Cost Net PMPM	\$95.33	

Top moving indications and most notable drug changes within the indications are as follows:

- **Inflammatory Conditions:** Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$335k (18.3%) to current \$2.2m.
 - Plan Cost Net PMPM ↓ \$.76 (-4.6%) to current \$15.66.
 - Patient Count ↑78 to current count of 300.
 - Adjusted Rxs ↑337 to current count of 1,601.
- **Notable Drug Changes within Indication:**
 - **Rinvoq:**
 - Previous ranked 4th, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$149k (98.4%) to current \$300k.
 - Plan Cost Net PMPM ↑ \$.82 (59.9%) to current \$2.18.
 - Patient Count ↑5 to current count of 16.
 - Adjusted Rxs ↑32 to current count of 84.
 - **Skyrizi Pen:**
 - Previous ranked 5th, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net ↑ \$84k (55.3%) to current \$235k.
 - Plan Cost Net PMPM ↑ \$.34 (25.2%) to current \$1.70.
 - Patient Count ↑4 to current count of 13.
 - Adjusted Rxs ↑22 to current count of 69.
 - **Adalimumab-Ryvok(CF) Autoinject (Biosimilar for Humira(CF)Pen)**
 - New, currently ranked 8th by Plan Cost Net.
 - Plan Cost Net: New, current \$81k.
 - Plan Cost Net PMPM: New, current \$.59.
 - Patient Count: New, current count of 23.
 - Adjusted Rxs: New, current count of 82.

- **Humira(CF) Pen:**
 - Previous ranked 1st, currently ranked 10th by Plan Cost Net.
 - Plan Cost Net ↓ \$291k (-80.2%) to current \$72k.
 - Plan Cost Net PMPM ↓ \$2.74 (-84.0%) to current \$.52.
 - Patient Count ↓8 to current count of 23.
 - Adjusted Rxs ↓64 to current count of 99.

- **Diabetes:** Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$663k (52.9%) to current \$1.9m.
 - Plan Cost Net PMPM ↑ \$2.62 (23.2%) to current \$13.90.
 - Patient Count ↑451 to current count of 1,676.
 - Adjusted Rxs ↑3,982 to current count of 15,113.

- **Notable Drug Changes within Indication:**
 - **Mounjaro:**
 - Previous ranked 2nd, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$360k (137.7%) to current \$621k.
 - Plan Cost Net PMPM ↑ \$2.15 (91.6%) to current \$4.50.
 - Patient Count ↑164 to current count of 309.
 - Adjusted Rxs ↑1,034 to current count of 1,764.

 - **Ozempic:**
 - Previous ranked 1st, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$175k (48.6%) to current \$536k.
 - Plan Cost Net PMPM ↑ \$.64 (19.8%) to current \$3.89.
 - Patient Count ↑109 to current count of 351.
 - Adjusted Rxs ↑639 to current count of 1,749.

 - **Trulicity:**
 - Previous ranked 3rd, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↓ \$56k (-35.6%) to current \$101k.
 - Plan Cost Net PMPM ↓ \$.68 (-48.1%) to current \$.73.
 - Patient Count ↓34 to current count of 59.
 - Adjusted Rxs ↓179 to current count of 314.

- **Cancer:** Previous ranked 3rd, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net ↑ \$357k (41.3%) to current \$11.2m.
 - Plan Cost Net PMPM ↑ \$1.08 (13.9%) to current \$8.85.
 - Patient Count ↑41 to current count of 175.
 - Adjusted Rxs ↑158 to current count of 800.

- **Notable Drug Changes within Indication:**

- **Idhifa:**
 - New, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net: New, current \$169k.
 - Plan Cost Net PMPM: New, current \$1.23.
 - Patient Count: New, current count of 2.
 - Adjusted Rxs: New, current count of 5.

- **Venclexta:**
 - New, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net: New, current \$94k.
 - Plan Cost Net PMPM: New, current \$.68.
 - Patient Count: New, current count of 2.
 - Adjusted Rxs: New, current count of 11.

- **Lynparza:**
 - New, currently ranked 5th by Plan Cost Net.
 - Plan Cost Net: New, current \$83k.
 - Plan Cost Net PMPM: New, current \$.60.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 10.

- **Sprycel:**
 - New, currently ranked 6th by Plan Cost Net.
 - Plan Cost Net: New, current \$78k.
 - Plan Cost Net PMPM: New, current \$.56.
 - Patient Count: New, current count of 2.
 - Adjusted Rxs: New, current count of 9.

- **HIV:** Previous ranked 6th, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↑ \$355k (60.6%) to current \$939k.
 - Plan Cost Net PMPM ↑ \$1.55 (29.5%) to current \$6.80.
 - Patient Count ↑46 to current count of 111.
 - Adjusted Rxs ↑202 to current count of 503.

- **Notable Drug Changes within Indication:**
 - **Biktarvy:**
 - Previous ranked 6th, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↑ \$96k (36.0%) to current \$363k.
 - Plan Cost Net PMPM ↑ \$.23 (9.6%) to current \$2.63.
 - Patient Count ↑7 to current count of 23.
 - Adjusted Rxs ↑24 to current count of 105.

- **Descovy:**
 - Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$138k (134.4%) to current \$240k.
 - Plan Cost Net PMPM ↑ \$.82 (89.0%) to current \$1.74.
 - Patient Count ↑24 to current count of 40.
 - Adjusted Rxs ↑92 to current count of 157.

- **Rukobia:**
 - Previous ranked 11th, currently ranked 5th by Plan Cost Net.
 - Plan Cost Net ↑ \$41k (533.4%) to current \$49k.
 - Plan Cost Net PMPM ↑ \$.28 (410.6%) to current \$.35.
 - Patient Count: Remains at 1.
 - Adjusted Rxs ↑5 to current count of 6.

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP PPO plan)
- PEBP PPO is outperforming the peer in Plan Cost Net,
- PEBP PPO experienced Plan Cost Net PMPM of \$102.65 compared to peer of \$130.06.
- Peer experienced Trend of 20.9%, compared to PEBP PPO of 7.7%.

Total Overall Trend	% Change	
Current Period - Plan Cost Net PMPM	\$96.74	
Utilization	\$3.95	4.3%
Unit Cost	\$2.69	2.9%
Member Share	(\$1.15)	(1.3%)
Total Change in Plan Cost Net PMPM	\$5.49	6.0%
Previous Period - Plan Cost Net PMPM	\$91.25	

Summary of Total – Overall the main driver of Trend was Specialty Utilization driven by an increase of 19.0% in Specialty patients. This resulted in a 16.8% increase in Specialty Days of Therapy.

Trend was mitigated by increased rebates of 25.4%. This produced a negative Unit Cost Trend of (-12.5%) on Specialty drugs and reduced NonSpecialty Unit Cost Trend to 14.2%, combined is 2.9%. There were also significant reductions in multiple rare conditions that contributed to a negative Unit Cost Trend.

Member Cost was mitigating to Trend on Specialty drugs, in part due to the reduction in Unit Cost. Member Cost contributed to trend on Nonspecialty drugs. This is due to increased Utilization and Drug Mix of more expensive brand drugs.

Key Statistics:

Nevada PEBP Total			
Description	Q2 FY25	Q2 FY24	Change
Average Members per Month	51,168	48,640	5.2%
Number of Unique patients	32,714	31,289	4.6%
Members Utilizing the Benefit	63.9%	64.3%	-0.4
Gross Cost/Adjusted Rx	\$148.48	\$138.69	7.1%
Plan Spend	\$49,447,442	\$42,382,450	16.7%
Rebates (estimated)	\$19,746,109	\$15,751,660	25.4%
Plan Cost Net	\$29,701,332	\$26,630,790	11.5%
Plan Cost Net PMPM	\$96.74	\$91.25	6.0%
Non-Specialty Plan Cost Net PMPM	\$45.33	\$37.77	20.0%
Specialty Plan Cost Net PMPM	\$51.42	\$53.48	9.7%
Generic Fill Rate	85.7%	85.1%	0.6
90 Day Utilization	59.8%	60.8%	-1.4
Retail - Maintenance 90 Utilization	29.7%	28.5%	1.2
Home Delivery Utilization	30.1%	32.3%	-2.2
Member Cost Net %	17.3%	17.3%	0.0

END OF REPORT